Potentially Modifiable Dementia Risk Factors in Canada: An Analysis of Canadian Longitudinal Study on Aging with a Multi-Country Comparison

Surim Son MSc[1,2]; Mark Speechley PhD[1]; Guangyong Zou PhD[1,3]; Miia Kivipelto MD PhD[4,5,6,7] ; Francesca Mangialasche MD PhD[4,6]; Howard Feldman MD[8,9]; Howard Chertkow MD[10,11]; Sylvie Belleville PhD[12,13]; Haakon Nygaard MD PhD[14]; Vladimir Hachinski MD DSc[1,3,15]; Pieruccini- Faria F PhD[2,16]; Manuel Montero-Odasso MD PhD[1,2,16*]

[1] Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada

[2] Gait and Brain Lab, Parkwood Institute, Lawson Health Research Institute, London, Ontario, Canada

[3] Robarts Research Institute, University of Western Ontario, London, Ontario, Canada

[4] Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden

[5] Neuroepidemiology and Ageing Research Unit, School of Public Health, Imperial College London, London, United Kingdom

[6] Theme Inflammation and Aging, Medical Unit Aging, Karolinska University Hospital, Stockholm, Sweden

[7] Stockholms Sjukhem, Research and Development Unit, Stockholm, Sweden

[8] UC San Diego, Alzheimer's Disease Cooperative Study, La Jolla, United States of America

[9] UC San Diego, Department of Neurosciences, La Jolla, United States of America

[10] Baycrest Hospital, Kimel Centre for Brain Health and Wellness and Anne & Allan Bank Centre for Clinical Research Trials, Toronto, Canada

[11] Canadian Consortium on Neurodegeneration in Aging (CCNA), Administration, Ontario, Canada

[12] Institut Universitaire de Gériatrie de Montréal, Research Center, Montreal, Canada

[13] Université de Montréal, Department of Psychology, Montreal, Canada

[14] Division of Neurology and Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC

[15] Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada

[16] Department of Medicine, Division of Geriatric, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada

[*]**Corresponding author:** Manuel Montero-Odasso, Departments of Medicine (Geriatrics) and Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada. **mmontero@uwo.ca**

Abstract

INTRODUCTION: Previous estimates suggested that 40% of dementia cases worldwide are associated with modifiable risk factors, however, these estimates are not known in Canada. We aimed to estimate the population impact of 12 risk factors in Canada, addressing potential differences by sex and age groups, and to compare with other countries.

METHODS: Prevalence and Population Attributable Fraction (PAF) of 12 modifiable risk factors were estimated using the Canadian Longitudinal Study on Aging baseline dataset (N=26,777).

RESULTS: Risk factors with the largest PAF were physical inactivity (11.3%), hearing loss (6.9%), and obesity (6.9%). Combined PAF of all risk factors was 49%, and it increased with age. The prevention potential was greater in men (54.1%) than in women (50.5%).

CONCLUSIONS: Nearly 50% of dementia cases in Canada could be prevented by modifying 12 risk factors across the lifespan and Canadian risk reduction strategies should prioritize targeting physical inactivity, hearing loss, and obesity.

Keywords
Dementia, prevention, risk reduction, lifestyle, risk factor, epidemiology

1. INTRODUCTION

With rapid global population aging, the number of individuals living with dementia worldwide is expected to triple, from 57 million to 152 million, by 2050.[1] In Canada, dementia prevalence is projected to increase by 66% by 2031.[2] Dementia is a multifactorial syndrome that results from multiple pathologies including those that cause neurodegeneration as well as vascular, metabolic and inflammatory processes that are associated with potentially modifiable risk factors.[3,4] Lifestyle interventions offer a promising non-pharmacological approach to reducing dementia burden by tempering modifiable risk factors. Risk reduction can potentially be reached through individual and public health approaches, which could complements emerging disease-modifying treatments directed at the pathological processes.[4]

The 2020 Lancet Commission Report on Dementia Prevention, Intervention, and Care[5] indicated that up to 40% of dementia cases worldwide are attributable to 12 modifiable factors comprising health behaviours, illnesses, and environmental exposures across the lifespan, known as the life course model of dementia prevention. This estimation is based on the weighted population attributable fraction (PAF), which quantifies the contribution of a given risk factor to dementia by combining both prevalence and the association between risk factor and disease, such as risk ratio, while adjusting for intercorrelation among risk factors.

Following the Lancet series,[5,6] the population impact of dementia risk factors has been estimated in other countries with differences in risk factor profiles.[7-12] Given that the same analytical approach and risk ratio were used to estimate PAF in all the studies, the differences in PAF across countries are mainly driven by differences in risk factor prevalence. For instance, less education is a greater contributing factor to dementia than social isolation in low-income countries as they tend to have stronger social ties and social support but have limited access to education compared to high-income countries.[9] Despite being one of the high-income countries with a universal health care system, Canada

now more than ever needs dementia risk reduction strategies, as it is reaching the super-aged country status, where it has ≥ 20% of its population composed of older adults.[13] However, no studies have estimated the population impact of the life-course model of modifiable risk factors for dementia in Canada, which is crucial for guiding evidence-based decision-making in the development of reduction strategies.

Besides the 12 risk factors included in the life course model of dementia prevention, the Lancet Commission Reports also identified sleep and diet as emerging risk factors.[5,6] Given the number of intervention trials delivering sleep and diet interventions to improve cognition, it is timely to quantify their population impact.[14,15] Estimating the population impact of diet is challenging due to the difficulty in measuring the diet pattern. For sleep, a recent study estimated that 5.7% of dementia cases are attributable to unhealthy sleep duration, using UK Biobank data.[16] However, the population impact of a sleep disturbance encompassing other conditions has not been estimated nor included in the life course model of dementia prevention.

Although air pollution is included in the life-course model[5], focusing only on lifestyle risk factors, rather than including an environmental risk factor, would be more beneficial in guiding the dementia risk reduction program.

Therefore, we aimed to estimate the prevalence and potential population impact of modifiable risk factors, including sleep disturbance, in Canadian adults using the largest Canadian population cohort study, and to compare the contribution of modifiable risk factors with other countries and by age groups and sex. Since the PAF of dementia risk factors has not been estimated in Canada, this study is much needed to tailor and develop Canada's dementia risk reduction program.

2. METHODS

This was a cross-sectional analysis of baseline data from the Canadian Longitudinal Study on Aging (CLSA) Comprehensive cohort. We followed STROBE guidelines for a cross-sectional study and conducted analyses using the *survey* and *psy* package in R Version 4.2.0.

2.1 Data source

CLSA is a prospective cohort study following 51,388 Canadians aged 45-85 years at recruitment for 20 years.[17] Participants were recruited to either Tracking or Comprehensive cohorts, which differed in sampling methods and data availability, as described elsewhere.[17] The comprehensive cohort was used as it included participants who had undergone detailed and comprehensive face-to-face assessments that included a neuro-cognitive battery, sensory-vision, audiometry, proprioception testing as well as physical and mobility assessments. Individuals with a diagnosis of cognitive impairment and or dementia, full-time members of the armed forces, residents of First Nations reserves, territories, or long-term care institutions (only those that provide 24 hours of nurse care), and those who could not respond in English or French at recruitment were excluded.[17] Baseline data were collected from 2012 to 2015.[17]

2.2 Risk factors

A total of 12 risk factors were identified using operational definitions from the Lancet report[5] and 2 initial PAF estimation studies for dementia.[18,19] Definitions are summarized in Table 1 and Supporting information panel 1.

2.3 Statistical Analysis

Participants with missing data on any risk factors were excluded. Demographic characteristics of those excluded were compared with included participants using independent sample t-tests and Chi-square tests, where appropriate.

To build the life-course model, the prevalence of midlife and later life risk factors was calculated for the age group 45-64 and 65-85, respectively. Early life risk factors were calculated for all age groups. The prevalence estimates were weighted with inflation weights to account for differences in selection probabilities.[20]

As described elsewhere,[9] PAF of each risk factor was calculated using Levin's formula and risk factor overlap was adjusted by applying Norton's formula[19] (see supporting information Panel 2 for detailed description). Relative risk was taken from the Lancet report[5] for all risk factors except sleep disturbance, which was derived from a recent meta-analysis of 18 longitudinal studies assessing the association between sleep disturbance and dementia.[21]

To compare our results with global estimates[5] and other countries,[7-11] we obtained the prevalence and PAF from other studies that utilized the Lancet[5] approach. The life-course model obtained from CLSA was qualitatively compared to the global estimate[5] and other countries – USA,[7] India,[9] Latin America,[9] China,[9] New Zealand,[8] Brazil,[11] Australia,[10] and Denmark.[12] A total of 9 risk factors were available across all the studied countries – less education, hearing loss, hypertension, obesity, smoking, depression, social isolation, physical inactivity, and diabetes – and were measured using similar definitions across studies.

To further explore differences in risk factor distribution by age groups and sex, analyses were stratified by 4 age groups (45-54, 55-64, 65-74, and 75-85) and sex and chi-square tests were conducted. A sensitivity analysis compared changes in prevalence and PAF with different risk factor definitions. To reflect both controlled and uncontrolled hypertension, both self-reported and systolic blood pressure of ≥140 mmHg were used to re-classify hypertension. Depression was re-operationalized as a 10-item Center for Epidemiologic Studies Depression Scale score of ≥10 to reflect depressive symptom. Excessive alcohol use was re-defined using Canadian guidance, which is drinking ≥7 standard drinks

per week.[22] A five-point Steptoe social isolation index was derived to incorporate cohabitation, social contact and participation into social isolation with a cut-off of ≥3.

3. RESULTS

A total of 26,777 participants were included (Table 2). The mean age was 59.6 years (SD 10.2) and 52% were female. The majority were white (90%), living in urban areas (90%), and 75% were married. Compared to excluded individuals, included participants were more likely to be younger, white, married, and have a higher education level and income (Table S1 in Supporting information).

3.1 Prevalence

The most prevalent risk factor was later life physical inactivity (83%) (Table 3), followed by later life sleep disturbance (40%), midlife obesity (30%), and midlife hearing loss (20%). The least common risk factors were midlife hypertension (8.5%), midlife smoking (5.5%) and social isolation (1.3%) in later life. The prevalence of physical inactivity was much higher than in other countries, which ranged from 15.3% in India to 62.8% in USA, except Australia (82%), as shown in Table 4. Hypertension prevalence (8.5%) was similar to the global Lancet estimate (8.9%), however, it was substantially lower compared to other countries, ranging from 17.2% to 56.6%. Smoking (5.5%) and social isolation (1.3%) were noticeably less prevalent than in other countries.

3.2 PAF

The weighted individual and combined PAF of all risk factors in Canada are presented in Table 3 and Figure 1. Almost 50% of dementia cases in Canada were attributed to 12 risk factors (PAF 49.4%, 95% CI 31.2-65.1) – nearly 12 points more than the worldwide estimate of 37.4% (Table 4). The PAF of the nine risk factors available in other studied countries ranged between 36% and 55.9%. When using these nine risk factors, the combined PAF in Canada (40%) was higher than in USA (36%), Denmark (35%)

and Australia (35.5%) but lower than in Latin America (55.9%). The combined PAF of the nine risk factors in Canada was similar to India, China, and Brazil, with a range from 40% and 42.1% (Table 4).

Of the 12 risk factors, later life physical inactivity had the largest weighted PAF in Canada, contributing 11.3% (95% CI 7.3-14.5). The PAF of midlife hearing loss and midlife obesity in Canada was 6.9% for each of them (95% CI 3.8-10.0 for hearing loss and 95% CI 4.2-8.4 for obesity). Later life smoking, midlife excessive alcohol use, and later life social isolation were associated with less than 2% of PAF in Canada. Compared to other countries, Canadian weighted PAFs were smaller for early life less education, midlife hypertension, later life smoking and social isolation, and larger for later life physical inactivity, midlife obesity and excessive alcohol use (Table 4).

3.3 By Sex and Age groups

Prevalence of the most common risk factors differed across sexes (Table 5). Among women, 79.9% had physical inactivity and 20.8% had depression, as compared to 72.7% and 11.8% in men. The prevalence of less education, hypertension, smoking, and sleep disturbance was similar between sexes (p>0.05). The prevalence of hearing loss, traumatic brain injury, excessive alcohol use, diabetes, and social isolation was higher in men than women (p<0.001).

Overall, the 12 risk factors accounted for 50.5% (31.6-66.7) of dementia among women and 54.1% (34.3- 70.3) among men (Table 5). PAF of hearing loss and traumatic brain injury was higher in men, whereas PAF of depression was higher in women.

Prevalence and PAF also varied across age groups (Table 5). From age 45-54 to 75-85 years, prevalence increased from 13.4% to 81.2% for hearing loss, 8.5% to 37.0% for less education, 16.5% to 21.9% for hypertension, 71.5% to 87.8% for physical inactivity, and 4.2% to 12.0% for diabetes. The highest prevalence of traumatic brain injury (15.4%) and smoking (13.7%) was observed at age 45-54 years, which declined after age 55 years and dropped to 8.9% and 3.9% at age 75-85 years,

respectively. Depression prevalence increased from 16.4% in age 45-54 to 20.6% in 55-64 years, then decreased to 9.0% in 75-85 years.

The combined PAF of all 12 risk factors increased with age. The combined PAF were 46.1% (28.3-62.1) in age 45-54 years, 54.9% (34.9-71.5) in 55-64 years, 61.2% (39.8-77.3) in 65-74 years, and 68.2% (45.6-83.1) in 75-85 years. Physical inactivity had the highest PAF among ages 45-54 years (10.2%, 6.4-13.5) and 55-64 years (10.5%, 6.8-13.4), while hearing loss had the largest PAF among ages 65-74 years (14.7%, 9.3-18.1) and 75-85 years (20.0%, 13.8-22.8). The estimated communality and unadjusted PAFs by age groups and sex are shown in Table S2-S3 in Supporting information.

3.4 Sensitivity Analyses

Operationalizing risk factors with different definitions increased the prevalence and PAF, and also changed the rank of risk factors with the largest PAF (Table S4-6 in Supporting information). The prevalence increased to 16% for depression, 29% for hypertension, 30% for excessive alcohol use, and 42% for social isolation. The largest change was observed with social isolation, and its prevalence increased from 1.3% to 42%. The combined PAF increased to 56.4% (36.6-71.6). Later life social isolation became the risk factor with the second largest PAF. In older age groups, hypertension and social isolation had larger PAF than obesity, whereas only hypertension had a larger PAF than obesity in both males and females.

4. DISCUSSION

Our results suggest that up to 49% of dementia cases in Canada could be delayed or prevented by modifying 12 risk factors including sleep disturbance. To our knowledge, this is the first study estimating the potential population impact of 12 modifiable risk factors for dementia in this country and the first to include sleep disturbance in a life-course model with participants as young as 45 years.

The predominant contributors were later life physical inactivity, midlife hearing loss and obesity. In contrast, later life smoking, midlife excessive alcohol use, and later life social isolation had substantially less contribution. Interestingly, aligned with the worldwide secular trend,[23] hypertension showed less impact than other studied countries. Finally, we observed greater prevention potential in men than women.

Over 80% of Canadians were not meeting physical activity guidelines, and nearly 40% of Canadians had impaired sleeping. Furthermore, 1 in 3 Canadians were obese, and 1 in 5 Canadians showed hearing loss. The estimated prevalence of obesity, physical inactivity, diabetes, and sleep disturbance was similar to previous estimates but our results showed a higher prevalence of less education and a lower prevalence of smoking and hearing loss.[24,25]

Canada's national dementia strategy includes the promotion of healthy lifestyle to reduce dementia risk, such as initiatives and programs to prevent and manage cardiovascular diseases and promote physical activity.[24,26] This high prevalence of physical inactivity is found despite sustained national efforts to promote physical activity. It highlights the need to advocate and implement moderate-to-vigorous exercise programs for older adults to help them meet physical activity targets. For instance, aerobic and resistance exercises have been shown to improve cognition in older adults and can be delivered in exercise programs.[27,28] More innovative approaches which provide paid-for programs in high-trafficked community institutions such as the YMCAs or online training done in the home environment are worth exploration.

The prevalence of hypertension remained comparatively lower than other risk factors. When self-reported hypertension was considered, its prevalence increased from 8.5% to 29%, underscoring the opportunity to improve both vascular and cognitive health. This relatively low prevalence of vascular risk factors, such as hypertension and diabetes, may reflect the extensive development of a national strategic plan for hypertension prevention and control in Canada since the 1990s, including a sodium

reduction strategy.[29] Yet, a high prevalence of obesity may be associated with a high prevalence of physical inactivity.

Despite an unclear underlying mechanism between hearing loss and dementia, a meta-analysis of 8 longitudinal studies found a 19% lower risk of cognitive decline among individuals with corrected versus uncorrected hearing loss (HR 0.81, 95% CI 0.76-0.87).[30] These findings suggest that dementia prevention programs and primary health care providers should consider encouraging hearing tests and hearing aid use. Compared to other lifestyle strategies, addressing hearing loss faces challenges related to stigma and affordability of hearing aids.[31] Given its high PAF and associated barriers, there is a pressing need to enhance hearing health care besides promoting patient education.

Sleep disturbance had a substantial contribution to dementia and the high prevalence we found is noteworthy because it can be translated to large potential population health benefits were it to be successfully addressed. Non-pharmacological interventions for sleep disturbance or disorder include sleep hygiene education, physical activity, and in some cases, bright light therapy,[32] however their effectiveness in preventing cognitive impairment requires further study. Periodically screening sleep impairment in practice will help identify and intervene undiagnosed sleep impairment.

Our age-specific analysis indicated that up to 46% of dementia cases could be prevented if we can modify all 12 risk factors as early as at age 45, and the potential for dementia prevention increased to 68% at age 75. Importantly, prevalence of physical inactivity, obesity, and sleep disturbance was already high at age 45-54. These results support the recommendation of commencing risk reduction interventions at midlife or earlier, before developing cognitive impairment.[33]

As with other studies ascertaining sex-specific estimates,[34-36] the prevalence of hearing loss and excessive alcohol use were higher in men while depression and physical inactivity were more prevalent in women. Contrary to our results, sex differences in smoking were observed in previous studies.[34-36]

The combined PAF of the nine risk factors was 33.2% globally and ranged between 35% and 55.9% among studied countries. The proportion of potentially preventable dementia cases in Canada was similar to studies from low- and middle-income countries, but higher than those from other high-income countries. Latin America reported the highest PAF, using data from 6 Latin American countries.[9]

The risk factor with the highest PAF was less education in middle- and low-income countries, while it was physical inactivity and obesity in high-income countries, suggesting a sociocultural gradient in dementia risk factors. Interestingly, risk factor profiles varied even among high-income countries, highlighting the uniqueness of the Canadian population which could inform policymakers in Canada. For instance, despite cultural similarities between USA and Canada, the prevalence of hearing loss, depression, and alcohol use was 2 to 4 times higher in Canada while USA had more than 1.5 times higher prevalence of obesity, diabetes, and hypertension.[7] Despite geographical distance, the risk factor profile of Canada was fairly similar to Australia and Denmark. This underpins the importance of identifying population-specific risk factor profiles to inform researchers and policymakers on developing dementia risk reduction strategies. International differences in risk factor prevalence could also reflect healthcare and policy contexts. For instance, the relatively lower prevalence of less education and smoking in high-income countries might be explained by the implementation of governmental compulsory education[37] and tobacco control policies.[38]

The primary strength of our study is the use of CLSA, the largest and well-characterized cohort study in Canada. Its large sample allowed us to explore how risk factor distributions differ from midlife to later life. Our study is the first to show dementia risk factor distributions across 4 age groups beginning at age 45.

There are several limitations. First, some risk factors were defined based on self-reported data and misclassification of risk factors may impact the estimated PAF. For example, depression and sleep

disturbance were classified based on self-reported measures, although using valid instruments. Physical inactivity excluded light activities. However, because our sensitivity analyses produced higher estimates of PAF than our main analysis, our estimates probably underestimate PAF. Second, our sample was composed by largely highly educated White Canadians, living in urban settings, which limits generalizability. Third, Levin's formula produces a biased estimate of PAF when adjusted relative risk is used. Considering that the adjusted relative risk for dementia risk factors tends to be less than the unadjusted relative risk, our obtained PAF may be underestimated.[39] Although diet is recognized as an important dementia risk factor[40] it was not included due to the complexities of analyzing diet. Lastly, while most of the risk factors had similar definitions, caution is needed in comparing the prevalence and PAF across studies.

Our results have critical implications for healthcare professionals, increasing their awareness of dementia risk factors and promoting the screening of prevalent risk factors to facilitate patient's risk reduction strategies from midlife. Furthermore, the findings could help researchers and policymakers design optimal prevention programs to ease the projected burden of dementia. Although today the β-amyloid-targeting therapies in early symptomatic Alzheimer's disease started to show promising results,[41,42] there is emerging evidence that the beneficial effect of lifestyle intervention are independent of β-amyloid pathology.[43] The FINGER trial showed that a multidomain intervention including exercise, nutritional counselling, cognitive training, social stimulation, and cardiometabolic management, improved cognition and reduced cognitive decline risk in 1,260 community dwellers at risk of dementia.[44] The FINGER model is being adapted and tested globally within the World-Wide FINGERS network of multidomain trials for dementia risk reduction[14], with Canada being at the forefront of such efforts with the CAN-THUMBS UP project.[45] Findings from the present study can inform the refinement and development of the CAN-THUMBS UP multidomain interventions. Additionally, combining lifestyle intervention with disease-modifying therapy will offer an even better

opportunity to effectively and precisely manage and prevent dementia based on patient's risk profiles, as demonstrated in diabetes management,[46] and multidomain lifestyle-based interventions combined with repurposed drugs (metformin) are now being tested in Europe.[47] Importantly, not all older adults at risk of dementia will be candidates for emerging disease-modifying therapy due to the therapies contraindications and limited generalizability of the current trial results, and therefore lifestyle interventions may be more applicable.[48] Analyses of the most prevalent combinations of risk factors and risk factor clustering would allow the development of impactful personalized prevention programs.

In conclusion, we determined that nearly up to 50% of dementia cases in Canada can be prevented by modifying 12 risk factors across the life span. The most prominent modifiable risk factors were physical inactivity, obesity, and hearing loss, whereas excessive alcohol use, smoking, and social isolation had substantially less contribution.

Authors contribution

Son had full access to all the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Son, Speechley, Montero-Odasso

Acquisition, analysis, or interpretation of data: Son, Speechley, Zou, Montero-Odasso

Drafting of the manuscript: Son

Revised the manuscript for important intellectual content: All authors

Statistical analysis: Son

Administrative, technical, or material support: Son, Speechley, Montero-Odasso

Supervision: Speechley, Zou, Montero-Odasso

Acknowledgement

Surim Son was awarded Alzheimer Society London and Middlesex Doctoral scholarship, Ontario Scholarship Award, and CCNA Trainee Synapse Challenge Funding.

Source of Funding

This project was funded by Gait and Brain Health program via fundings of the Canadian Institute of Health and Research (MOP 211220, PJT 153100). This research was made possible using the data/biospecimens collected by the Canadian Longitudinal Study on Aging (CLSA). Funding for the CLSA is provided by the Government of Canada through the Canadian Institutes of Health Research (CIHR) under grant reference: LSA 94473 and the Canadian Foundation for Innovation as well as the following provinces, Newfoundland, Nova Scotia, Quebec, Ontario, Manitoba, Alberta, and British Columbia. This research has been conducted using the CLSA Baseline Comprehensive version 7.0, under Application Number 2109006, title "Potential modifiable risk factors for low cognition and dementia in Canadian Longitudinal Study of Aging", and was approved by the CLSA on January 28, 2022. The CLSA is led by Drs. Parminder Raina, Chrstina Wolfson, and Susan Kirkland.

The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of data, preparation, review, or approval of the manuscript and decision to submit the manuscript for publication.

Disclosures

Dr. Montero-Odasso reports grants from the CIHR including the Institute of Aging, the CCNA, and Weston Foundation (Weston Brain Institute). He is on advisory boards for the Canadian Geriatrics Society (CGS) (serving as president) and the CIHR Institute of Aging, and the Research Executive Council of the CCNA. Prof. Kivipelto and Dr. Mangialasche are supported by FORTE grant 2023-

01125, and are both part of the WW-FINGERS Network Global Scientific Coordinating Center, which is supported by the Alzheimer Disease Data Initiative. Dr. Feldman reports grant funding from CIHR to the CCNA (CNA- 163902) and Annovis (QR Pharma), Vivoryon (Probiodrug), AC Immune, and LuMind; service agreements for consulting activities with LuMind, Genentech (DSMB), Roche/Banner (DMC), Tau Consortium (SAB), Samus Therapeutics, Biosplice Therapeutics, Axon Neurosciences, Novo Nordisk Inc., Janssen Research & Development LLC; and travel funding from World Events Forum (ADDF) with no personal funds received and all payments to UCSD. He also reports a philanthropic donation from the Epstein Family Alzheimer's Disease Collaboration for therapeutic research in AD with no personal funds received and all payments to UCSD. Dr. Belleville reports grant funding to CCNA from CIHR and ASC. She also reports consulting fees and participation on an advisory board for Lucilab and an unpaid role of scientific advisor for the Quebec Federation of Alzheimer's Societies. Dr. Nygaard reports consulting fees from Hoffman-La Roche and Biogen. AL reports a Centre for Aging Brain Health Innovation Grant (CCNA-1-00295). As Scientific Director of CCNA, Dr. Cherkow reports grants from CIHR, Baycrest Health Sciences Foundation, Women's Brain Health Initiative, Alzheimer Society of Canada, Brain Canada, Saskatchewan Health Research Foundation, Alberta Innovates, and Weston Foundation (Weston Brain Institute). As a site investigator for clinical trials, he also receives support from Roche, Lilly, Anavex, and Alector. He reports being a member of the Ministerial Advisory Board on Dementia (2019-2022) and part of the membership organizing committee for Canadian Conference on Dementia. Drs. Montero-Odasso, Chertkow, Belleville, Feldman, and Nygaard are co-principal investigators of CAN-THUMB UP. Dr. Speechley is part of the steering committee for CAN-THUMBS UP. Dr. Hachinksi reports support from the Weston Foundation (Weston Brain Institute). Son, Drs. Zou and Peruccini-Faria have no competing interests to declare.

Data Sharing

Data are available from the Canadian Longitudinal Study on Aging (www.clsa-elcv.ca) for researchers who meet the criteria for access to de-identified CLSA data.

References

1. GBD Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. *Lancet Public Health*. Feb 2022;7(2):e105-e125. doi:10.1016/S2468-2667(21)00249-8

2. Alzheimer Society of C. Report summary Prevalence and monetary costs of dementia in Canada (2016): a report by the Alzheimer Society of Canada. *Health Promot Chronic Dis Prev Can*. Oct 2016;36(10):231-232. Note de synthese Prevalence et couts financiers des maladies cognitives au Canada : un rapport de la Societe Alzheimer du Canada (2016).

3. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. *Alzheimers Dement*. Jun 2015;11(6):718-26. doi:10.1016/j.jalz.2015.05.016

4. Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. *Nat Rev Neurol*. Nov 2018;14(11):653-666. doi:10.1038/s41582-018-0070-3

5. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet*. Aug 8 2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6

6. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. *Lancet*. Dec 16 2017;390(10113):2673-2734. doi:10.1016/S0140-6736(17)31363-6

7. Lee M, Whitsel E, Avery C, et al. Variation in Population Attributable Fraction of Dementia Associated With Potentially Modifiable Risk Factors by Race and Ethnicity in the US. *JAMA Netw Open*. Jul 1 2022;5(7):e2219672. doi:10.1001/jamanetworkopen.2022.19672

8. Ma'u E, Cullum S, Cheung G, Livingston G, Mukadam N. Differences in the potential for dementia prevention between major ethnic groups within one country: A cross sectional analysis of population attributable fraction of potentially modifiable risk factors in New Zealand. *Lancet Reg Health West Pac*. Aug 2021;13:100191. doi:10.1016/j.lanwpc.2021.100191

9. Mukadam N, Sommerlad A, Huntley J, Livingston G. Population attributable fractions for risk factors for dementia in low-income and middle-income countries: an analysis using cross-sectional survey data. *Lancet Glob Health*. May 2019;7(5):e596-e603. doi:10.1016/S2214-109X(19)30074-9

10. See RS, Thompson F, Russell S, et al. Potentially modifiable dementia risk factors in all Australians and within population groups: an analysis using cross-sectional survey data. *Lancet Public Health*. Sep 2023;8(9):e717-e725. doi:10.1016/S2468-2667(23)00146-9

11. Suemoto CK, Mukadam N, Brucki SMD, et al. Risk factors for dementia in Brazil: Differences by region and race. *Alzheimers Dement*. May 2023;19(5):1849-1857. doi:10.1002/alz.12820

12. Jorgensen K, Nielsen TR, Nielsen A, Waldemar G. Potential for prevention of dementia in Denmark. *Alzheimers Dement*. Oct 2023;19(10):4590-4598. doi:10.1002/alz.13030

13. Flanagan A, Dunning, J., Wong, I., Brierley, A., MacDonald, BJ., Sinha, SK. *Enabling a More Promising Future for Long-Term Care in Canada*. 2023.

14. Kivipelto M, Mangialasche F, Snyder HM, et al. World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. *Alzheimers Dement*. Jul 2020;16(7):1078-1094. doi:10.1002/alz.12123

15. Montero-Odasso M, Ismail Z, Livingston G. One third of dementia cases can be prevented within the next 25 years by tackling risk factors. The case "for" and "against". *Alzheimers Res Ther*. Jul 8 2020;12(1):81. doi:10.1186/s13195-020-00646-x

16. Chen H, Cao Y, Ma Y, Xu W, Zong G, Yuan C. Age- and sex-specific modifiable risk factor profiles of dementia: evidence from the UK Biobank. *Eur J Epidemiol*. Jan 2023;38(1):83-93. doi:10.1007/s10654-022-00952-8

17. Raina PS, Wolfson C, Kirkland SA, et al. The Canadian longitudinal study on aging (CLSA). *Can J Aging*. Sep 2009;28(3):221-9. doi:10.1017/S0714980809990055

18. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. *Lancet Neurol*. Sep 2011;10(9):819-28. doi:10.1016/S1474-4422(11)70072-2

19. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. *Lancet Neurol*. Aug 2014;13(8):788-94. doi:10.1016/S1474-4422(14)70136-X

20. Canadian Longitudinal Study on Aging. *CLSA Technical Report 2023: Sampling and Computation of Response Rates and Sample Weights for the Tracking (Telephone Interview) Participants and Comprehensive Participants*. 2023. https://www.clsa-elcv.ca/doc/5130

21. Shi L, Chen SJ, Ma MY, et al. Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis. *Sleep Med Rev*. Aug 2018;40:4-16. doi:10.1016/j.smrv.2017.06.010

22. Paradis C, Butt P, Shield K, et al. *Canada's Guidance on Alcohol and Health: Final Report*. 2023.

23. NCD Risk Factor Collaboration. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. *Lancet*. Sep 11 2021;398(10304):957-980. doi:10.1016/S0140-6736(21)01330-1

24. Public Health Agency of Canada. *A dementia strategy for Canada: 2021 Annual report*. 2021.

25. Ramage-Morin PL., Banks R., Pineault D., Atrach M., H. G. *Hypertension associated with hearing health problems among Canadian adults aged 19 to 79 years*. 2021. *Health Reports*.

26. Public Health Agency of Canada. *A dementia strategy for Canada*. 2019.

27. Montero-Odasso M, Zou G, Speechley M, et al. Effects of Exercise Alone or Combined With Cognitive Training and Vitamin D Supplementation to Improve Cognition in Adults With Mild Cognitive Impairment: A Randomized Clinical Trial. *JAMA Netw Open*. Jul 3 2023;6(7):e2324465. doi:10.1001/jamanetworkopen.2023.24465

28. Northey JM, Cherbuin N, Pumpa KL, Smee DJ, Rattray B. Exercise interventions for cognitive function in adults older than 50: a systematic review with meta-analysis. *Br J Sports Med*. Feb 2018;52(3):154-160. doi:10.1136/bjsports-2016-096587

29. Schiffrin EL, Campbell NR, Feldman RD, Kaczorowski J, Lewanczuk R, Padwal R, Tobe SW. Hypertension in Canada: Past, Present, and Future. *Ann Glob Health*. Mar-Apr 2016;82(2):288-99. doi:10.1016/j.aogh.2016.02.006

30. Yeo CD, Yeom SW, You YS, Kim JS, Lee EJ. Association of sudden sensorineural hearing loss with increased risk of insomnia: a nationwide population-based cohort study. *J Clin Sleep Med*. May 1 2022;18(5):1335-1342. doi:10.5664/jcsm.9864

31. Jenstad L, Moon J. Systematic Review of Barriers and Facilitators to Hearing Aid Uptake in Older Adults. *Audiol Res*. May 10 2011;1(1):e25. doi:10.4081/audiores.2011.e25

32. Zee PC, Vitiello MV. Circadian Rhythm Sleep Disorder: Irregular Sleep Wake Rhythm Type. *Sleep Med Clin*. Jun 1 2009;4(2):213-218. doi:10.1016/j.jsmc.2009.01.009

33. Solomon A, Stephen R, Altomare D, et al. Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services-part 4 of 6. *Alzheimers Res Ther*. Oct 11 2021;13(1):171. doi:10.1186/s13195-021-00875-8

34.   Borelli WV, Leotti VB, Strelow MZ, Chaves MLF, Castilhos RM. Preventable risk factors of dementia: Population attributable fractions in a Brazilian population-based study. *Lancet Reg Health Am*. Jul 2022;11:100256. doi:10.1016/j.lana.2022.100256

35.   Nianogo RA, Rosenwohl-Mack A, Yaffe K, Carrasco A, Hoffmann CM, Barnes DE. Risk Factors Associated With Alzheimer Disease and Related Dementias by Sex and Race and Ethnicity in the US. *JAMA Neurol*. Jun 1 2022;79(6):584-591. doi:10.1001/jamaneurol.2022.0976

36.   Vergara RC, Zitko P, Slachevsky A, San Martin C, Delgado C. Population attributable fraction of modifiable risk factors for dementia in Chile. *Alzheimers Dement (Amst)*. 2022;14(1):e12273. doi:10.1002/dad2.12273

37.   Besche-Truthe F. The global trajectories of compulsory education: clustering sequences of policy development. *Global Pathways to Education Global Dynamics of Social Policy*. Palgrave Macmillan, Cham. ; 2021.

38.   Anderson CL, Becher H, Winkler V. Tobacco Control Progress in Low and Middle Income Countries in Comparison to High Income Countries. *Int J Environ Res Public Health*. Oct 24 2016;13(10)doi:10.3390/ijerph13101039

39.   Darrow LA, Steenland NK. Confounding and bias in the attributable fraction. *Epidemiology*. Jan 2011;22(1):53-8. doi:10.1097/EDE.0b013e3181fce49b

40.   World Health Organization. *Risk reduction of cognitive decline and dementia: WHO guidelines*. 2019.

41.   Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *JAMA*. Jul 17 2023;doi:10.1001/jama.2023.13239

42.   van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. *N Engl J Med*. Jan 5 2023;388(1):9-21. doi:10.1056/NEJMoa2212948

43.   Dhana K, Agarwal P, James BD, et al. Healthy Lifestyle and Cognition in Older Adults With Common Neuropathologies of Dementia. *JAMA Neurol*. Feb 5 2024;doi:10.1001/jamaneurol.2023.5491

44.   Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. *Lancet*. Jun 6 2015;385(9984):2255-63. doi:10.1016/S0140-6736(15)60461-5

45.   Feldman HH, Belleville S, Nygaard HB, et al. Protocol for the Brain Health Support Program Study of the Canadian Therapeutic Platform Trial for Multidomain Interventions to Prevent Dementia (CAN-THUMBS UP): A Prospective 12-Month Intervention Study. *J Prev Alzheimers Dis*. 2023;10(4):875-885. doi:10.14283/jpad.2023.65

46.   Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care*. Jan 2004;27(1):155-61. doi:10.2337/diacare.27.1.155

47.   Barbera M, Lehtisalo J, Perera D, et al. A multimodal precision-prevention approach combining lifestyle intervention with metformin repurposing to prevent cognitive impairment and disability: the MET-FINGER randomised controlled trial protocol. *Alzheimers Res Ther*. Jan 31 2024;16(1):23. doi:10.1186/s13195-023-01355-x

48.   Manly JJ, Deters KD. Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed? *JAMA*. Aug 8 2023;330(6):510-511. doi:10.1001/jama.2023.11704

Table 1. Definition of 12 risk factors

Risk factor	Definition
Less Education	Less than secondary school graduation
Hearing loss	>25 dB at 500, 1000, 2000 and 4000 Hz in the better ear
Traumatic brain injury	A head injury caused by vehicular crash, fall, or sports-related activities that resulted in losing consciousness
High blood pressure	>140 mmHg (average of 5 measurements at a time of assessment)
Excessive Alcohol use	>21 unit of alcohol per week
Obesity	BMI of $\geq$30 kg/m^2
Smoking	Current cigarette smoker (in past 30 days)
Depression	Self-report diagnosis
Social isolation	Less than monthly social contact (get together) with family, friends, or neighbours who live outside of their household
Physical inactivity	<150 minutes of moderate-to-vigorous physical activity per week or <75 minutes of vigorous activity per week
Diabetes	Self-report diagnosis
Sleep disturbance	Self-report current indicator of poor sleep quality, insomnia symptom, sleep apnea, daytime sleepiness, and restless leg syndrome over the last month

Table 2. Participant characteristics (Weighted N = 3,342,7841)

	Overall (N = 26,777)
Age, years	59.6 (10.2)
Age groups	
45 - 54	6,820 (39.0%)
55 - 64	8,848 (31.0%)
65 - 74	6,553 (18.0%)
75+	4,556 (11.0%)
Sex	
Women	13,610 (52.0%)
Men	13,167 (48.0%)
Ethnicity	
Non-white	1,116 (5.9%)
White	25,661 (94.0%)
Education	
Less than secondary school education	1,375 (16.0%)
Secondary school graduation	2,484 (11.0%)
Some post-secondary education	1,950 (9.1%)
Post-secondary degree/diploma	20,968 (63.0%)
Marital status	
Single	2,275 (8.2%)
Married	18,664 (75.0%)
Widowed/Divorced/Separated	5,833 (17.0%)
Income	
<$20,000	1,228 (5.9%)
$20,000 - $50,000	5,499 (22.0%)
$50,000 - $100,000	8,938 (34.0%)
$100,000 - $150,000	5,002 (20.0%)
>$150,000	4,436 (18.0%)
Province	
Alberta	2,515 (10.0%)
British Columbia	5,631 (29.0%)
Manitoba	2,734 (7.1%)
Newfoundland and Labrador	1,992 (2.0%)
Nova Scotia	2,699 (3.8%)
Ontario	5,811 (17.0%)

Quebec	5,395 (31.0%)
Region	
Pacific	5,631 (29.0%)
Prairie	5,249 (17.0%)
Central	11,206 (48.0%)
Atlantic	4,691 (5.8%)
Rurality	
Rural	2,160 (5.2%)
Urban	23,524 (90.0%)
Peri-urban	1,093 (4.4%)

Data are mean (SD) or n (%)

Table 3. PAF for 12 modifiable risk factors for dementia in Canada

	Risk factors	RR	Communality (%)	Prevalence (%)	Unweighted PAF (%)	Weighted PAF (%)
Early life	Less education	1.6 (1.3-2.0)	44.8	16.0	8.8	4.0 (2.3-5.4)
Midlife	Hearing loss	1.9 (1.4-2.7)	43.7	20.0	15.3	6.9 (3.8-10.0)
	Traumatic brain injury	1.8 (1.5-2.2)	25.6	15.0	10.7	4.8 (3.6-6.0)
	Hypertension	1.6 (1.2-2.2)	33.4	8.5	4.9	2.2 (0.9-3.6)
	Excessive alcohol	1.2 (1.1-1.3)	39.1	12.0	2.3	1.1 (0.6-1.4)
	Obesity	1.6 (1.3-1.9)	53.3	30.0	15.3	6.9 (4.2-8.4)
Later life	Smoking	1.6 (1.2-2..2)	60.4	5.5	3.2	1.4 (0.6-2.4)
	Depression	1.9 (1.6-2.3)	48.6	12.0	9.8	4.4 (3.4-5.3)
	Social isolation	1.6 (1.3-1.9)	10.1	1.3	0.8	0.4 (0.2-0.5)
	Physical inactivity	1.4 (1.2-1.7)	30.8	83.0	24.9	11.3 (7.3-14.5)
	Type 2 diabetes	1.5 (1.3-1.8)	48.4	12.0	5.7	2.6 (2.3-3.4)
	Sleep disturbance	1.2 (1.1-1.3)	42.0	40.0	7.4	3.4 (2.0-4.2)
	Combined PAF					49.4 (31.2-65.1)

Abbreviations: PAF, population attributable fraction; RR, risk ratio

Table 4. Prevalence and weighted PAF of 12 potentially modifiable dementia risk factors over the life course in Canada compared to the estimates reported in other countries

	Risk factors	Canada		Global[5]		US[7]		India[9]		Latin America[9]		China[9]		New Zealand[8]		Brazil[11]		Australia[10]		Denmark[12]	
		Prev (%)	wPAF (%)	Prev (%)	wPAF (%)	Prev (%)	wPAF (%)	Prev (%)	wPAF (%)	Prev (%)	wPAF (%)	Prev (%)	wPAF (%)	Prev (%)	wPAF (%)	Prev (%)	wPAF (%)	Prev (%)	wPAF (%)	Prev (%)	wPAF (%)
Early life	Less education†	16.0	4.0	40.0	7.1	10.7	2.0	92.2	13.6	68.8	10.9	75.9	10.8	31.0	4.6	46.6	7.7	10.0	1.9	9.5	1.9
Mid life	Hearing loss†	20.0	6.9	31.7	8.2	10.8	3.0	22.3	6.4	28.8	7.7	14.3	3.9	39.9	7.8	26.5	6.8	26.6	7.0	23.1	6.4
	Traumatic brain injury	15.0	4.8	12.1	3.4	17.1	4.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	3.7	12.1	3.1	n/a	n/a	4.7	1.4
	Hypertension†	8.5	2.2	8.9	1.9	42.2	6.8	19.3	4.0	56.6	9.3	38.1	6.4	33.5	4.9	46.4	7.6	17.2	3.3	22.5	4.3
	Excessive alcohol	12.0	1.1	11.8	0.8	3.6	0.2	n/a	n/a	n/a	n/a	n/a	n/a	9.8	0.6	4.3	0.3	8.2	0.5	9.4	0.6
	Obesity†	30.0	6.9	3.4	0.7	44.0	7.1	13.7	2.9	44.8	7.9	32.0	5.6	38.4	5.5	31.4	5.6	38.8	6.6	22.7	4.3
	Smoking†	5.5	1.4	27.4	5.2	8.5	1.7	39.9	6.4	30.0	5.7	23.0	4.2	13.5	2.2	10.6	2.1	6.7	1.4	12.2	2.4
	Depression†	12.0	4.4	13.2	3.9	7.4	2.1	5.2	1.7	23.9	6.6	1.5	0.5	19.1	4.3	15.8	4.4	11.6	3.3	8.0	2.4
Later life	Social isolation†	1.3	0.4	11.0	3.5	11.9	2.3	10.4	2.3	0.5	0.1	3.4	0.7	53.6	5.2	1.6	0.3	5.2	1.0	8.3	1.6
	Physical inactivity†	83.0	11.3	17.7	1.6	62.8	6.8	15.3	2.2	34.2	4.5	50.7	5.8	37.3	5.4	36.7	4.5	82.0	8.3	67.6	7.5
	Diabetes†	12.0	2.6	6.4	1.1	28.6	4.2	9.3	1.7	18.5	3.2	9.4	1.6	11.6	1.6	19.7	3.1	16.8	2.7	13.2	2.4
	Sleep disturbance	40.0	3.4	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Combined PAF of all risk factors			49.4		37.4		40.3		41.2		55.9		39.5		45.8		45.5		36.0		35.2
Combined PAF of 9 risk factors†			40.0		33.2		36.0		41.2		55.9		39.5		41.5		42.1		35.5		35.2

Prev, Prevalence; wPAF, Weighted population attributable fraction

* Weighted PAF was calculated based on the data provided in Lee et al. (2022)[7]

† Risk factors available across all studies

n/a Not available

Table 5. Weighted prevalence and PAF of 12 potentially modifiable risk factors by 4 age groups and sex in Canada

Risk factors	Overall Prevalence (%)	Weighted PAF (%)	45-54 Prevalence (%)	Weighted PAF (%)	55-64 Prevalence (%)	Weighted PAF (%)	65-74 Prevalence (%)	Weighted PAF (%)	75-85 Prevalence (%)	Weighted PAF (%)	p*	Female Prevalence (%)	Weighted PAF (%)	Male Prevalence (%)	Weighted PAF (%)	p*
Less education	16.1	3.8	8.5	2.2	12.9	3.2	25.2	5.9	37.0	8.6	<0.001	16.6	3.9	15.6	3.7	0.18
Hearing loss	33.2	10.0	13.4	5.0	28.6	9.1	54.2	14.7	81.2	20.0	<0.001	29.7	9.0	37.2	11.0	<0.001
Traumatic brain injury	13.8	4.3	15.4	5.0	14.1	4.5	12.8	4.2	8.9	3.2	<0.001	10.2	3.2	17.7	5.4	<0.001
Hypertension	11.7	2.8	6.5	1.7	10.9	2.7	18.0	4.4	21.9	5.5	<0.001	11.7	2.8	11.8	2.9	0.12
Excessive alcohol use	11.5	1.0	10.9	1.0	12.5	1.1	12.4	1.1	9.8	0.9	<0.001	6.4	0.5	17.1	1.4	<0.001
Obesity	30.2	6.6	27.1	6.4	34.1	7.6	32.7	7.3	25.7	6.3	<0.001	29.7	6.5	30.7	6.8	0.007
Smoking	10.7	2.6	13.7	3.5	12.0	3.0	6.5	1.7	3.9	1.1	<0.001	10.7	2.6	10.8	2.7	0.05
Depression	16.5	5.6	16.4	5.9	20.6	7.0	14.3	5.1	9.0	3.5	<0.001	20.8	6.7	11.8	4.2	<0.001
Social isolation	1.6	0.4	1.9	0.5	1.4	0.4	0.9	0.3	1.8	0.5	0.003	1.0	0.2	2.2	0.6	<0.001
Physical inactivity	76.5	10.1	71.5	10.2	76.6	10.5	79.8	10.8	87.8	12.3	<0.001	79.9	10.3	72.7	9.9	<0.001
Diabetes	8.4	1.7	4.2	0.9	10.0	2.1	12.3	2.6	12.0	2.7	<0.001	6.9	1.4	9.9	2.1	<0.001
Sleep disturbance	42.9	3.4	42.9	3.6	45.2	3.7	39.5	3.3	41.6	3.6	0.004	42.0	3.3	43.7	3.5	0.05
Combined PAF		52.5		46.1		54.9		61.2		68.2			50.5		54.1	

PAF, Population attributable fraction

* Chi-square test comparing the prevalence of risk factor by age groups or sex

Figure 1. Weighted PAF for 12 modifiable risk factors for dementia in Canada